Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Novo Nordisk is contesting Sen. Bernie Sanders' calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. In late April, the Senate Health, Education, Labor, and Pensions ...